Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable Prognosis when Adjuvant Mifamurtide is Combined with High-Dose Ifosfamide By Ogkologos - August 28, 2025 136 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ISG/OS-2 and GEIS-33 studies Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Community Comes Together To Give Terminally Ill Father One Last Christmas... October 18, 2021 FDA Approves Crizotinib for ALK-positive Inflammatory Myofibroblastic Tumour July 25, 2022 Physical Activity May Lessen the Effects of Chemobrain, Study Finds August 26, 2021 Fewer Women with Ovarian, Breast Cancer Undergo Genetic Testing than Expected April 9, 2019 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Elinzanetant For AYAs with Advanced Cancer, Study Finds Serious Communication Gaps about... Loss of Y Chromosome in Men Makes Bladder Cancer More Aggressive Tyrosine Kinase Inhibitor Prolongs Progression-Free Survival in Rare Neuroendocrine Tumours [ESMO...
